Neurosense Historical Balance Sheet
| NRSN Stock | USD 0.86 0.07 7.53% |
Trend analysis of Neurosense Therapeutics balance sheet accounts such as Net Tangible Assets of 10.9 M provides information on Neurosense Therapeutics' total assets, liabilities, and equity, which is the actual value of Neurosense Therapeutics to its prevalent stockholders. By breaking down trends over time using Neurosense Therapeutics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Neurosense Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Neurosense Therapeutics is a good buy for the upcoming year.
Neurosense Therapeutics Inventory |
|
Neurosense |
About Neurosense Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Neurosense Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Neurosense Therapeutics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Neurosense Therapeutics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Neurosense currently owns. An asset can also be divided into two categories, current and non-current.
Neurosense Therapeutics Balance Sheet Chart
Add Fundamental
Total Assets
Total assets refers to the total amount of Neurosense Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Neurosense Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Neurosense Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Neurosense Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Net Tangible Assets
The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.Most accounts from Neurosense Therapeutics' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Neurosense Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.At this time, Neurosense Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 13th of December 2024, Cash And Short Term Investments is likely to grow to about 4.9 M, though Total Stockholder Equity is likely to grow to (1.8 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 558K | 1.2M | 1.9M | 2.0M | Total Assets | 11.4M | 7.7M | 3.2M | 5.3M |
Neurosense Therapeutics balance sheet Correlations
Click cells to compare fundamentals
Neurosense Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Pair Trading with Neurosense Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Neurosense Stock
Moving against Neurosense Stock
| 0.7 | DYAI | Dyadic International | PairCorr |
| 0.57 | ESPR | Esperion Therapeutics | PairCorr |
| 0.56 | BMY | Bristol Myers Squibb | PairCorr |
| 0.37 | FLGC | Flora Growth Corp | PairCorr |
| 0.34 | DNA | Ginkgo Bioworks Holdings | PairCorr |
The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.
The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.65) | Return On Assets (1.51) | Return On Equity (4.95) |
The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.